000950 重药控股
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入59,692,6582.24%80,119,10767,829,01062,520,75545,219,571
减:营业总成本59,058,4342.77%79,031,58066,608,40261,148,24544,064,665
    其中:营业成本55,254,3723.04%73,810,39362,008,78056,782,32940,985,178
               财务费用813,810-17.39%1,302,0281,094,2351,087,649701,598
               资产减值损失(9,789)113.87%(27,756)(39,943)(12,883)(8,912)
公允价值变动收益7,048778.46%16,1622,318126,88317,452
投资收益241,91919.37%301,548293,349302,690287,978
    其中:对联营企业和合营企业的投资收益243,69521.61%291,454286,195279,408284,769
营业利润548,069-30.45%1,007,0951,435,0111,560,9271,371,385
利润总额547,081-31.16%1,008,5411,472,4901,580,2861,374,461
减:所得税费用140,238-18.21%236,042309,496289,613227,070
净利润406,844-34.73%772,4991,162,9951,290,6731,147,391
减:非控股权益114,6188.47%117,542210,719285,229263,046
股东净利润292,226-43.54%654,957952,2761,005,444884,344

市场价值指针
每股收益 (元) *0.170-43.33%0.3800.5500.5800.510
每股派息 (元) *0.030--0.0500.0600.105--
每股净资产 (元) *6.6173.84%6.5076.1105.6335.113
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容